Last reviewed · How we verify

FZ-AD004

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

FZ-AD004 is a Small molecule drug developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.. It is currently in Phase 1 development. Also known as: FZ-AD004-Antibody-drug Conjugate.

At a glance

Generic nameFZ-AD004
Also known asFZ-AD004-Antibody-drug Conjugate
SponsorShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about FZ-AD004

What is FZ-AD004?

FZ-AD004 is a Small molecule drug developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd..

Who makes FZ-AD004?

FZ-AD004 is developed by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (see full Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. pipeline at /company/shanghai-fudan-zhangjiang-bio-pharmaceutical-co-ltd).

Is FZ-AD004 also known as anything else?

FZ-AD004 is also known as FZ-AD004-Antibody-drug Conjugate.

What development phase is FZ-AD004 in?

FZ-AD004 is in Phase 1.

Related